- Published on
Infectious Disease - Candidiasis
CANDIDIASIS
DESCRIPTION • Candida is a yeast that constitutes part of the normal flora on the skin and within the gastrointestinal and genitourinary tracts. • Candida species are an emerging cause of bloodstream infections in immunocompromised individuals. • Candida can induce both superficial and systemic infections.
Epidemiology: Candidal infections can affect individuals of all ages; however, they are more prevalent among the elderly, babies, and pregnant women.
• A recent study revealed that up to 9% of bloodstream infections in US hospitals were associated with candidal infection.
– Numerous varieties of Candida exist, with Candida albicans being the primary organism associated with the majority of illnesses. Non-albicans Candida species are rising in prevalence. In a recent specimen
Among over 1400 Candida specimens from hospitalized patients, the most prevalent species following C. albicans were C. parapsilosis, C. glabrata, and C. tropicalis.
RISK FACTORS • Immune suppression/neutropenia (2) • Preexisting conditions associated with immune suppression, including cancer, AIDS, and significant burns
• Extended antibiotic administration • Indwelling intravenous catheter • Chemotherapeutic treatment • Recipients of solid organ and bone marrow transplants • Total parenteral nutrition • Chronic renal insufficiency and hemodialysis • Gastrointestinal perforation • Diabetes mellitus • Gestation • Glucocorticoid therapy
GENERAL PREVENTION
• Prudent use of antibiotics. • Extraction of central venous catheters when no longer required.
PATHOPHYSIOLOGY
• Candidemia may arise from disruptions in mucosal barriers at any location within the gastrointestinal system. • Candidemia may also result from the colonization of intravascular catheter devices.
ETIOLOGY • The genus Candida has over 150 species, with the clinically significant species being C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, C. krusei, C. guilliermondii, and C. lusitaniae. • C. albicans is responsible for over 50% of candidemia cases.
FREQUENTLY CO-OCCURRING CONDITIONS
Immunosuppression due to chemotherapy, HIV/AIDS, solid organ or bone marrow transplantation, neutropenia, or severe underlying conditions necessitating extended ICU admissions with intravenous catheters.
DIAGNOSTIC HISTORY
The clinical presentation and assessment of risk factors are contingent upon the affected organ (e.g., genitourinary and intestinal tracts, brain, skin) and the severity of the disease.
• Vulvovaginal candidiasis: Itching, discomfort, painful urination, painful intercourse, and white, curd-like discharge.
• Oropharyngeal candidiasis: Intermittent discomfort, taste impairment, occasionally asymptomatic.
• Candida esophagitis: Nausea, vomiting, retrosternal chest discomfort, odynophagia, dysphagia.
• Invasive candidiasis: History of immunosuppressive therapy, HIV/AIDS, concomitant malignancy. Mental status alterations may occur if sepsis.
PHYSICAL EXAMINATION
• It is contingent upon the affected organ and the severity of the condition.
• Vulvovaginal candidiasis: Erythema of the vulva or vagina accompanied by a white, curd-like discharge. Occasionally, there is a transparent discharge.
• Oral candidiasis (thrush) and Candida esophagitis: Presence of white plaques on the tongue, hard palate, and soft palate. Frequently results in an erythematous base upon removal. Patients may exhibit esophageal candidiasis in the absence of oral involvement.
Candidemia presents with symptoms ranging from fever to indications of severe sepsis, including hypotension, tachycardia, and alterations in mental status.
DIAGNOSTIC TESTS AND INTERPRETATION Laboratory
• Vulvovaginal candidiasis: Often a clinical diagnosis. The pH of vaginal discharge may vary between 4 and 4.5. Yeast will be observed in microscopic examinations of KOH preparations or wet mounts (3,4).
• Oral candidiasis (thrush): Frequently diagnosed clinically as well. Confirmation can be achieved by examining scrapings on KOH preparations using light microscopy.
Esophageal candidiasis may necessitate endoscopy and biopsy for diagnosis.
Candidemia: Gram staining or proliferation in blood cultures. Candida must not be regarded as a blood contamination.
Susceptibility testing for fluconazole should be conducted in cases of severe infection or in affected people.
ineffective against first-line treatments.
Imaging: Preliminary Strategy
• Neurological assessment: CT scan and MRI of the brain.
• Endocarditis: Transesophageal echocardiography • Esophagitis: Upper endoscopy with biopsy
• Spleen and liver: MRI surpasses CT
Pneumonia: Chest X-ray, Computed Tomography
• Peritonitis: Fluid aspiration guided by CT or ultrasound
Subsequent Actions & Specific Considerations
• For candidemia: Provide general ICU care for stabilization, as death rates may exceed 30–40%.
5–10% of candidemia cases are associated with endophthalmitis complications. Ophthalmology must be consulted in every instance of candidemia.
Diagnostic Procedures/Additional Candida esophagitis: While endoscopy and biopsy represent the definitive method for identifying Candida esophagitis, numerous individuals receive empirical treatment when they exhibit significant symptoms alongside risk factors and oral manifestations.
Candidiasis. It is important to note that oral candidiasis is not a prerequisite for esophageal candidal infections.
Pathological Observations
Yeast exhibiting and lacking pseudohyphae
DIFFERENTIAL DIAGNOSIS
• Oral hairy leukoplakia • Contact dermatitis • Atrophic vaginitis • Bacterial sepsis • Endocarditis • Fever of unknown origin • Cytomegalovirus (CMV) esophagitis
INITIAL THERAPEUTIC AGENT
• Vulvovaginal candidiasis: Various topical treatments are accessible, such as butoconazole cream 5 g/day for 3 days. Oral alternatives are also accessible, including fluconazole 150 mg administered orally as a single dose. Prolonged treatment duration is necessary in severe cases or immunocompromised individuals. Administration of butoconazole cream for 5 to 7 days, or oral fluconazole for up to 7 days, may be required (5–7).
• Oral candidiasis (thrush): Nystatin oral solution (suspension), clotrimazole oral troche, or fluconazole 100–200 mg/day. The therapeutic duration typically spans 5 days following the resolution of symptoms.
Candida esophagitis: Administer Fluconazole 400 mg as a first dose, followed by 200–400 mg daily for a duration of 7–14 days. This can be administered orally, but may be delivered intravenously in certain patients with pronounced dysphagia or odynophagia.
• Candidemia: The selection of empirical therapy is contingent upon the
Candida should undergo culture and sensitivity testing for triazoles (e.g., fluconazole) (8,9). In stable, non-neutropenic patients devoid of antifungal exposure, fluconazole (800 mg intravenously once, followed by 400 mg intravenously daily) is a judicious option. All other patients, including those who are unstable, neutropenic, have prior antifungal exposure, or have experienced recent or extended hospitalizations, should receive empirical treatment with either an echinocandin (caspofungin, micafungin, or anidulafungin), voriconazole, or lipid formulations of amphotericin B. This may be modified to fluconazole if the sample exhibits sensitivity.
C. krusei exhibits resistance to fluconazole.
C. glabrata frequently exhibits resistance to triazoles.
C. parapsilosis isolates have elevated minimum inhibitory concentrations (MICs) to echinocandins.
C. lusitaniae exhibits resistance to amphotericin B. The advised length of antifungal treatment is a minimum of 2 weeks following the negative results of blood cultures. Verify the implementation of adequate "source control" (e.g., intravenous lines have been removed and substituted).
Esophageal candidiasis: In instances of fluconazole resistance, alternative triazoles, including itraconazole, posaconazole, and voriconazole, shown efficacy. An echinocandin, such as caspofungin, micafungin, or anidulafungin, may be utilized in
Patients who are hospitalized can only receive it in intravenous form.
SUPPLEMENTARY THERAPY
Concerns for Referral
Infectious disease specialists should be sought for bloodstream Candida infections and for guidance in managing neutropenic patients.
Pharmacists are invaluable due to the numerous drug interactions associated with antifungal drugs, particularly the triazoles. Exercise caution when concurrently administering warfarin, rifampin, antiepileptic drugs, and sulfonylureas.
OPERATIONS/ADDITIONAL INTERVENTIONS
A surgical consultation is necessary to drain fluid collections infected with Candida species and to manage candidal endocarditis.
INPATIENT CONSIDERATIONS
Criteria for Admission
Patients suspected with candidemia should be hospitalized and administered empiric antifungal medication.
CONTINUING MANAGEMENT POST-TREATMENT GUIDELINES
Patient Surveillance
QT prolongation must be monitored via ECGs in patients administered triazoles (e.g., fluconazole, voriconazole).
• The pharmacy must evaluate potential drug interactions while administering antifungal medicines, particularly triazoles.
• Conduct daily blood cultures in patients with candidemia to confirm sterilization.
• Ophthalmology should evaluate all patients with candidemia for endophthalmitis.
OUTLOOK
Mortality progressively rises in patients with candidemia who have a delay in antifungal treatment. For instance, individuals treated three or more days after confirmed candidemia exhibit mortality rates above 40%.
COMPLICATIONS • Renal failure • Esophageal perforation • Endocarditis • Endophthalmitis • Meningitis • Peritonitis and adhesions • Pericarditis • Abscess • Mortality
CANDIDIASIS
DESCRIPTION • Candida is a yeast that constitutes part of the normal flora on the skin and within the gastrointestinal and genitourinary tracts. • Candida species are an emerging cause of bloodstream infections in immunocompromised individuals. • Candida can induce both superficial and systemic infections.
Epidemiology: Candidal infections can affect individuals of all ages; however, they are more prevalent among the elderly, babies, and pregnant women.
• A recent study revealed that up to 9% of bloodstream infections in US hospitals were associated with candidal infection.
– Numerous varieties of Candida exist, with Candida albicans being the primary organism associated with the majority of illnesses. Non-albicans Candida species are rising in prevalence. In a recent specimen
Among over 1400 Candida specimens from hospitalized patients, the most prevalent species following C. albicans were C. parapsilosis, C. glabrata, and C. tropicalis.
RISK FACTORS • Immune suppression/neutropenia (2) • Preexisting conditions associated with immune suppression, including cancer, AIDS, and significant burns
• Extended antibiotic administration • Indwelling intravenous catheter • Chemotherapeutic treatment • Recipients of solid organ and bone marrow transplants • Total parenteral nutrition • Chronic renal insufficiency and hemodialysis • Gastrointestinal perforation • Diabetes mellitus • Gestation • Glucocorticoid therapy
GENERAL PREVENTION
• Prudent use of antibiotics. • Extraction of central venous catheters when no longer required.
PATHOPHYSIOLOGY
• Candidemia may arise from disruptions in mucosal barriers at any location within the gastrointestinal system. • Candidemia may also result from the colonization of intravascular catheter devices.
ETIOLOGY • The genus Candida has over 150 species, with the clinically significant species being C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, C. krusei, C. guilliermondii, and C. lusitaniae. • C. albicans is responsible for over 50% of candidemia cases.
FREQUENTLY CO-OCCURRING CONDITIONS
Immunosuppression due to chemotherapy, HIV/AIDS, solid organ or bone marrow transplantation, neutropenia, or severe underlying conditions necessitating extended ICU admissions with intravenous catheters.
DIAGNOSTIC HISTORY
The clinical presentation and assessment of risk factors are contingent upon the affected organ (e.g., genitourinary and intestinal tracts, brain, skin) and the severity of the disease.
• Vulvovaginal candidiasis: Itching, discomfort, painful urination, painful intercourse, and white, curd-like discharge.
• Oropharyngeal candidiasis: Intermittent discomfort, taste impairment, occasionally asymptomatic.
• Candida esophagitis: Nausea, vomiting, retrosternal chest discomfort, odynophagia, dysphagia.
• Invasive candidiasis: History of immunosuppressive therapy, HIV/AIDS, concomitant malignancy. Mental status alterations may occur if sepsis.
PHYSICAL EXAMINATION
• It is contingent upon the affected organ and the severity of the condition.
• Vulvovaginal candidiasis: Erythema of the vulva or vagina accompanied by a white, curd-like discharge. Occasionally, there is a transparent discharge.
• Oral candidiasis (thrush) and Candida esophagitis: Presence of white plaques on the tongue, hard palate, and soft palate. Frequently results in an erythematous base upon removal. Patients may exhibit esophageal candidiasis in the absence of oral involvement.
Candidemia presents with symptoms ranging from fever to indications of severe sepsis, including hypotension, tachycardia, and alterations in mental status.
DIAGNOSTIC TESTS AND INTERPRETATION Laboratory
• Vulvovaginal candidiasis: Often a clinical diagnosis. The pH of vaginal discharge may vary between 4 and 4.5. Yeast will be observed in microscopic examinations of KOH preparations or wet mounts (3,4).
• Oral candidiasis (thrush): Frequently diagnosed clinically as well. Confirmation can be achieved by examining scrapings on KOH preparations using light microscopy.
Esophageal candidiasis may necessitate endoscopy and biopsy for diagnosis.
Candidemia: Gram staining or proliferation in blood cultures. Candida must not be regarded as a blood contamination.
Susceptibility testing for fluconazole should be conducted in cases of severe infection or in affected people.
ineffective against first-line treatments.
Imaging: Preliminary Strategy
• Neurological assessment: CT scan and MRI of the brain.
• Endocarditis: Transesophageal echocardiography • Esophagitis: Upper endoscopy with biopsy
• Spleen and liver: MRI surpasses CT
Pneumonia: Chest X-ray, Computed Tomography
• Peritonitis: Fluid aspiration guided by CT or ultrasound
Subsequent Actions & Specific Considerations
• For candidemia: Provide general ICU care for stabilization, as death rates may exceed 30–40%.
5–10% of candidemia cases are associated with endophthalmitis complications. Ophthalmology must be consulted in every instance of candidemia.
Diagnostic Procedures/Additional Candida esophagitis: While endoscopy and biopsy represent the definitive method for identifying Candida esophagitis, numerous individuals receive empirical treatment when they exhibit significant symptoms alongside risk factors and oral manifestations.
Candidiasis. It is important to note that oral candidiasis is not a prerequisite for esophageal candidal infections.
Pathological Observations
Yeast exhibiting and lacking pseudohyphae
DIFFERENTIAL DIAGNOSIS
• Oral hairy leukoplakia • Contact dermatitis • Atrophic vaginitis • Bacterial sepsis • Endocarditis • Fever of unknown origin • Cytomegalovirus (CMV) esophagitis
INITIAL THERAPEUTIC AGENT
• Vulvovaginal candidiasis: Various topical treatments are accessible, such as butoconazole cream 5 g/day for 3 days. Oral alternatives are also accessible, including fluconazole 150 mg administered orally as a single dose. Prolonged treatment duration is necessary in severe cases or immunocompromised individuals. Administration of butoconazole cream for 5 to 7 days, or oral fluconazole for up to 7 days, may be required (5–7).
• Oral candidiasis (thrush): Nystatin oral solution (suspension), clotrimazole oral troche, or fluconazole 100–200 mg/day. The therapeutic duration typically spans 5 days following the resolution of symptoms.
Candida esophagitis: Administer Fluconazole 400 mg as a first dose, followed by 200–400 mg daily for a duration of 7–14 days. This can be administered orally, but may be delivered intravenously in certain patients with pronounced dysphagia or odynophagia.
• Candidemia: The selection of empirical therapy is contingent upon the
Candida should undergo culture and sensitivity testing for triazoles (e.g., fluconazole) (8,9). In stable, non-neutropenic patients devoid of antifungal exposure, fluconazole (800 mg intravenously once, followed by 400 mg intravenously daily) is a judicious option. All other patients, including those who are unstable, neutropenic, have prior antifungal exposure, or have experienced recent or extended hospitalizations, should receive empirical treatment with either an echinocandin (caspofungin, micafungin, or anidulafungin), voriconazole, or lipid formulations of amphotericin B. This may be modified to fluconazole if the sample exhibits sensitivity.
C. krusei exhibits resistance to fluconazole.
C. glabrata frequently exhibits resistance to triazoles.
C. parapsilosis isolates have elevated minimum inhibitory concentrations (MICs) to echinocandins.
C. lusitaniae exhibits resistance to amphotericin B. The advised length of antifungal treatment is a minimum of 2 weeks following the negative results of blood cultures. Verify the implementation of adequate "source control" (e.g., intravenous lines have been removed and substituted).
Esophageal candidiasis: In instances of fluconazole resistance, alternative triazoles, including itraconazole, posaconazole, and voriconazole, shown efficacy. An echinocandin, such as caspofungin, micafungin, or anidulafungin, may be utilized in
Patients who are hospitalized can only receive it in intravenous form.
SUPPLEMENTARY THERAPY
Concerns for Referral
Infectious disease specialists should be sought for bloodstream Candida infections and for guidance in managing neutropenic patients.
Pharmacists are invaluable due to the numerous drug interactions associated with antifungal drugs, particularly the triazoles. Exercise caution when concurrently administering warfarin, rifampin, antiepileptic drugs, and sulfonylureas.
OPERATIONS/ADDITIONAL INTERVENTIONS
A surgical consultation is necessary to drain fluid collections infected with Candida species and to manage candidal endocarditis.
INPATIENT CONSIDERATIONS
Criteria for Admission
Patients suspected with candidemia should be hospitalized and administered empiric antifungal medication.
CONTINUING MANAGEMENT POST-TREATMENT GUIDELINES
Patient Surveillance
QT prolongation must be monitored via ECGs in patients administered triazoles (e.g., fluconazole, voriconazole).
• The pharmacy must evaluate potential drug interactions while administering antifungal medicines, particularly triazoles.
• Conduct daily blood cultures in patients with candidemia to confirm sterilization.
• Ophthalmology should evaluate all patients with candidemia for endophthalmitis.
OUTLOOK
Mortality progressively rises in patients with candidemia who have a delay in antifungal treatment. For instance, individuals treated three or more days after confirmed candidemia exhibit mortality rates above 40%.
COMPLICATIONS • Renal failure • Esophageal perforation • Endocarditis • Endophthalmitis • Meningitis • Peritonitis and adhesions • Pericarditis • Abscess • Mortality
0 Comments
